0001127602-23-006770.txt : 20230223
0001127602-23-006770.hdr.sgml : 20230223
20230223162111
ACCESSION NUMBER: 0001127602-23-006770
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230215
FILED AS OF DATE: 20230223
DATE AS OF CHANGE: 20230223
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dickinson Andrew D
CENTRAL INDEX KEY: 0001310204
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19731
FILM NUMBER: 23659961
MAIL ADDRESS:
STREET 1: 333 LAKESIDE DRIVE
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: GILEAD SCIENCES, INC.
CENTRAL INDEX KEY: 0000882095
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 943047598
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 333 LAKESIDE DR
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
BUSINESS PHONE: 6505743000
MAIL ADDRESS:
STREET 1: 333 LAKESIDE DR
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
FORMER COMPANY:
FORMER CONFORMED NAME: GILEAD SCIENCES INC
DATE OF NAME CHANGE: 19930328
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2023-02-15
0000882095
GILEAD SCIENCES, INC.
GILD
0001310204
Dickinson Andrew D
GILEAD SCIENCES, INC.
333 LAKESIDE DRIVE
FOSTER CITY
CA
94404
1
Chief Financial Officer
Common Stock
2023-02-15
5
A
0
E
376
56.3805
A
105618
D
The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of August 16, 2022 through February 15, 2023. This transaction is exempt under Rule 16b-3(c).
In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on August 16, 2022.
/s/ Edward S. Son by Power of Attorney for Andrew D. Dickinson
2023-02-23